Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Software giant SAP has overtaken Danish drugmaker Novo Nordisk to become Europe’s most valuable company, in the latest ...

Novo Nordisk A/S (NYSE:NVO) returned to full membership of the Association of the British Pharmaceutical Industry (ABPI) ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...